相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Immune-priming of the Tumor Microenvironment by Radiotherapy Rationale for Combination With Immunotherapy to Improve Anticancer Efficacy
Vafa Shahabi et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2015)
Current Clinical Trials Testing Combinations of Immunotherapy and Radiation
Mario Crittenden et al.
SEMINARS IN RADIATION ONCOLOGY (2015)
The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential Synergies
Leisha A. Emens et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Clinical development success rates for investigational drugs
Michael Hay et al.
NATURE BIOTECHNOLOGY (2014)
Classification of current anticancer immunotherapies
Lorenzo Galluzzi et al.
ONCOTARGET (2014)
Current status of granulocyte-macrophage colony-stimulating factor in the immunotherapy of melanoma
Howard L. Kaufman et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2014)
Combinations of immunotherapy and radiation in cancer therapy
Ralph E. Vatner et al.
FRONTIERS IN ONCOLOGY (2014)
Use of Multiple Endpoints and Approval Paths Depicts a Decade of FDA Oncology Drug Approvals
Michael B. Shea et al.
CLINICAL CANCER RESEARCH (2013)
Oncology Meets Immunology: The Cancer-Immunity Cycle
Daniel S. Chen et al.
IMMUNITY (2013)
Abagovomab As Maintenance Therapy in Patients With Epithelial Ovarian Cancer: A Phase III Trial of the AGO OVAR, COGI, GINECO, and GEICO-The MIMOSA Study
Paul Sabbatini et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Effect of Montanide and Poly-ICLC Adjuvant on Human Self/Tumor Antigen-Specific CD4+ T Cells in Phase I Overlapping Long Peptide Vaccine Trial
Takemasa Tsuji et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Vaccines for Melanoma and Renal Cell Carcinoma
Howard L. Kaufman
SEMINARS IN ONCOLOGY (2012)
The Tipping Point for Combination Therapy: Cancer Vaccines With Radiation, Chemotherapy, or Targeted Small Molecule Inhibitors
James W. Hodge et al.
SEMINARS IN ONCOLOGY (2012)
A methodological framework to enhance the clinical success of cancer immunotherapy
Axel Hoos et al.
NATURE BIOTECHNOLOGY (2011)
Therapeutic cancer vaccines: Why so few randomised phase III studies reflect the initial optimism of phase II studies
Angus G. Dalgleish
VACCINE (2011)
Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study
P. Quaglino et al.
ANNALS OF ONCOLOGY (2010)
Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
James L. Gulley et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2010)
Improved Endpoints for Cancer Immunotherapy Trials
Axel Hoos et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
Jedd D. Wolchok et al.
CLINICAL CANCER RESEARCH (2009)
Placebo-Controlled Phase III Trial of Patient-Specific Immunotherapy With Mitumprotimut-T and Granulocyte-Macrophage Colony-Stimulating Factor After Rituximab in Patients With Follicular Lymphoma
Arnold Freedman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon-α in metastatic melanoma patients
L Pilla et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Cancer immunotherapy: moving beyond current vaccines
SA Rosenberg et al.
NATURE MEDICINE (2004)
分享论文
